


Lipoprotein(a): Actionable Insights for Primary Prevention

What Is Lipoprotein(a)?



Lipoprotein(a), also known as Lp(a), is a critical, independent risk factor for ASCVD, largely determined by genetics.^{1,3,4}

Lp(a) Contributes to CVD Through Multiple Mechanisms

Elevated Lp(a) can



Accelerate plaque buildup^{4,5}



Promote inflammation^{4,5}




Increase thrombosis risk^{4,5}

How Does Lp(a) Impact CV Risk?


Elevated Lp(a) Is Associated With an Increased Risk for CAD

Incident Risk for CAD in Individuals With No Self-Reported CVD History⁶



Lp(a) Screening Helps to Accurately Characterize CVD Risk^{12,13}

ASCVD Relative Risk: Increase Compared With Population Median (20 nmol/L)^{a,12}




Lp(a) screening identifies patients who may be at **particularly high ASCVD risk**.¹³

4X Elevated Lp(a) means up to 4X the risk for a first heart attack.^{12,14}

^aThese estimates reflect UK Biobank data and are a general guide; risk may vary in other populations.¹²

Evolving Understanding of the Value of Lp(a) Is Reflected in Updated Testing Recommendations

Guidelines increasingly recommend Lp(a) testing for broader populations



^bPremature ASCVD is defined as occurring in men aged <55 years and women aged <65 years.¹³

Actionable Insights on Lp(a) Screening

**Who should get Lp(a) measured?**

Recently updated guidelines recommend testing every adult patient at least once in a lifetime.^{12,13,15,16}

**How do I test for Lp(a)?**

Although not included by default, Lp(a) testing can be easily added to a standard lipid panel at the time of routine cholesterol testing.¹⁷

**How are Lp(a) results interpreted?**

Low risk

Moderate risk

High risk^{7,18}

<75 nmol/L


75-<125 nmol/L

≥125 nmol/L

Practical Tips for Overall CV Risk Factor Management

Proactive Lp(a) testing enables more aggressive risk factor management (eg, tighter control of LDL), earlier or more timely initiation of treatment, and closer monitoring (eg, ordering imaging) to lower overall CV risk for patients with elevated Lp(a).¹⁹

For patients with elevated Lp(a), you can work together to put proactive measures in place to prevent CVD.



Glossary

AHA/ACC	American Heart Association/American College of Cardiology
AMI	Acute myocardial infarction
Apo(a)	Apolipoprotein(a)
ApoB	Apolipoprotein B-100
ASCVD	Atherosclerotic cardiovascular disease
CAD	Coronary artery disease
CI	Confidence interval
CV	Cardiovascular
CVD	Cardiovascular disease
ESC/EAS	European Society of Cardiology/European Atherosclerosis Society
KIV	Kringle IV
LDL-C	Low-density lipoprotein cholesterol
Lp(a)	Lipoprotein(a)
NLA	National Lipid Association

References

01

American Heart Association. Clinicians’ guide to frequently asked questions about lipoprotein(a) testing. <https://www.heart.org/en/-/media/Files/Professional/Quality-Improvement/Lpa/Clinicians-Guide-LPaFAQFINAL.pdf> (Accessed February 20, 2026).

02

Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. *Lancet*. 2024;404(10459):1255-1264.

03

Tsimikas S, Marcovina SM. Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week. *J Am Coll Cardiol*. 2022;80(9):934-946.

04

Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. *Arterioscler Thromb Vasc Biol*. 2022;42(1):e48-e60.

05

Centers for Disease Control and Prevention. About Lipoprotein (a). <https://www.cdc.gov/heart-disease-family-history/about/about-lipoprotein-a.html> (Accessed April 23, 2026).

06

Finneran P, Pampana A, Khetarpal SA, et al. Lipoprotein(a) and coronary artery disease risk without a family history of heart disease. *J Am Heart Assoc*. 2021;10(5):e017470.

07

Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. *J Clin Lipidol*. 2024;18(3):e308-e319.

08

ClinicalTrials.gov. A study to investigate the effect of lepodisiran on the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) - ACCLAIM-Lp(a). <https://clinicaltrials.gov/study/NCT06292013> (Accessed March 13, 2026).

09

ClinicalTrials.gov. Olpasiran trials of cardiovascular events and lipoprotein(a) reduction (OCEAN(a)) - outcomes trial. <https://clinicaltrials.gov/study/NCT05581303> (Accessed March 13, 2026).

10

ClinicalTrials.gov. Assessing the impact of muvalaplin on major cardiovascular events in adults with elevated lipoprotein(a) (MOVE-Lp(a)). <https://clinicaltrials.gov/study/NCT07157774> (Accessed March 13, 2026).

11

ClinicalTrials.gov. Assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with CVD (Lp(a)HORIZON). <https://clinicaltrials.gov/study/NCT04023552> (Accessed March 13, 2026).

12

Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC /NLA/PCNA Guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. *J Am Coll Cardiol*. 2026;87(19):2624-2757.

13

Reyes-Soffer G, Yeang C, Michos ED, et al. High lipoprotein(a): actionable strategies for risk assessment and mitigation. *Am J Prev Cardiol*. 2024;18:100651.

14

Kamstrup PR, Benn M, Tybjaerg-Hansen A, et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. *Circulation*. 2008;117(2):176-184.

15

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41(1):111-188.

16

Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. *Eur Heart J*. 2025;46(42):4359-4378.

17

Cleveland Clinic. Lipoprotein (a). <https://my.clevelandclinic.org/health/articles/25226-lipoprotein-a> (Accessed March 03, 2026).

18

Clinical Pathology Laboratories. Lipoprotein(a) reporting units change. <https://www.cpllabs.com/clinicians/client-communications/lruc/> (Accessed April 24, 2026).

19

Al-Dalakta A, Cho LS, Sarraju A. Lipoprotein(a) in clinical practice: What clinicians need to know. *Cleve Clin J Med*. 2025;92(11):679-685.

20

Perrot N, Verbeek R, Sandhu M, et al. Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. *Atherosclerosis*. 2017;256:47-52.

21

Family Heart Foundation. Lipoprotein(a) and your risk: it’s more than just a number. <https://familyheart.org/lipoproteina-and-your-risk-its-more-than-just-a-number> (Accessed March 06, 2026).